Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CRHBP | P24387 | 2/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL6669275 | 1.00 | GAA (0.44) | GAALMNAALDH1A1TP53TSHR | |
| SCHEMBL7200305 | 1.00 | GAA (0.44) | GAALMNAALDH1A1TP53TSHR | |
| SCHEMBL6121060 | 1.00 | GAA (0.44) | GAALMNAALDH1A1TP53TSHR | |
| SCHEMBL278292 | 0.97 | LMNA (0.42) | GAALMNAALDH1A1TP53TSHR | |
| SCHEMBL29008 | 0.97 | — | — | |
| SCHEMBL1933520 | 0.97 | LMNA (0.42) | GAALMNAALDH1A1TP53TSHR | |
| SCHEMBL4394616 | 0.97 | — | — | |
| SCHEMBL11522424 | 0.94 | LMNA (0.40) | GAALMNAALDH1A1TP53TSHR | |
| SCHEMBL10985053 | 0.94 | — | — | |
| Methane SCHEMBL29072799 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9445992-B2 | Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion | ARISGEN SA (CH) | 2016-09-20 | — | — | US | claimed |
| CN-102770152-B | The mucosal delivery of peptides | 阿瑞斯根股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| US-20120302502-A1 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ARISGEN SA (CH) | 2012-11-29 | — | — | US | claimed |
| EP-2504019-A2 | MUCOSAL DELIVERY COMPOSITION COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ArisGen SA (CH) | 2012-10-03 | — | — | EP | claimed |
| WO-2011064316-A2 | MUCOSAL DELIVERY OF PEPTIDES | BOTTI PAOLO (CH) | 2011-06-03 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9533048-B2 | Mucosal delivery of drugs | ARISGEN SA (CH) | 2017-01-03 | — | — | US | disclosed |
| US-9533048-B2 | Mucosal delivery of drugs | ARISGEN SA (CH) | 2017-01-03 | — | — | US | disclosed |
| US-9445992-B2 | Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion | ARISGEN SA (CH) | 2016-09-20 | — | — | US | disclosed |
| US-9445992-B2 | Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion | ARISGEN SA (CH) | 2016-09-20 | — | — | US | disclosed |
| US-20120302502-A1 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ARISGEN SA (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120302502-A1 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ARISGEN SA (CH) | 2012-11-29 | — | — | US | disclosed |
| EP-2504019-A2 | MUCOSAL DELIVERY COMPOSITION COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ArisGen SA (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064316-A2 | MUCOSAL DELIVERY OF PEPTIDES | BOTTI PAOLO (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2008037484-A2 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | BOTTI PAOLO (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-5684049-A | HIV-inhibiting benzeneacetamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | SLC2A1, SLC2A4, SLC2A9 | GAA 1109/4885LMNA 867/4885ALDH1A1 1145/4885 |
| US-20120302502-A1 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | VIP, CFTR, IAPP | GAA 1344/4885LMNA 1034/4885ALDH1A1 4849/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | GAA 643/4885LMNA 4376/4885ALDH1A1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.